In this episode, Martin examines Moderna and explains why he believes the market had priced in an exceptionally pessimistic outlook for the company. He breaks down its valuation, pipeline, commercial prospects, and the risks surrounding its future growth. Martin also analyzes Marvell Technology, Merck, and Broadcom, discussing their businesses, competitive positions, valuations, and the key factors shaping his investment outlook on each stock.